No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RYTM240517C45000
- 0.15
- 0.000.00%
15min DelayTrading May 17 09:43 ET
0.00High0.00Low
0.00Open0.15Pre Close0 Volume309 Open Interest45.00Strike Price0.00Turnover1431.87%IV18.50%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.15Time Value100Contract SizeAmericanOptions Type0.0790Delta0.0335Gamma254.00Leverage Ratio-13.1394Theta0.0000Rho20.07Eff Leverage0.0005Vega
Intraday
- 5D
- 1D
News
Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$153.26K in Common Stock
$Rhythm Pharmaceuticals(RYTM.US)$ Officer Shulman Joseph sold 3,984 shares of common stock on May 9, 2024 at an average price of $38.4685 for a total value of $153.26K.Source: Announcement What is sta
Press Release: Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals Announces New Employment Inducement Grants BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company fo
Anti-Obesity Drugs Global Strategic Business Report 2024-2030 Featuring F. Hoffmann-La Roche, GlaxoSmithKline, Eisai, Novo Nordisk, Rhythm Pharmaceuticals, and VIVUS - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Anti-Obesity Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Anti-Obesity Drugs Market to Reach $4.8 Billion b
Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Rhythm Pharmaceuticals Price Target Cut to $79.00/Share From $80.00 by Canaccord Genuity
Rhythm Pharmaceuticals Price Target Cut to $79.00/Share From $80.00 by Canaccord Genuity
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $79
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $80 to $79.
Comments
» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
5
» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
5
» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
5
Rhythm Pharmaceuticals' high P/S ratio is alarming due to its lower forecast growth compared to the industry. Future revenues may not sustain the positive sentiment, risking shareholders' investments and potential investors may pay a high premium. Investors should note the company's 2 warning signs.
Rhythm Pharmaceuticals' high P/S ratio and unstable revenue growth could be alarming for investors. Given the weak revenue forecast, share prices may risk a decline. Investor caution is advised.
Read more